Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Rani Takes Next Step As Oral Ustekinumab Biosimilar Enters The Clinic

As biosimilars to Stelara (ustekinumab) continue to advance in global markets, Rani Therapeutics has made progress for its proposed RT-111 orally administered ustekinumab biosimilar.

Biosimilars Value-Added Medicines

Amneal Outlines Ambitions To Become Leading Affordable Medicines Supplier In US

While it currently sits in fourth place, Amneal’s co-CEO Chirag Patel has laid out ambitions for the firm to become the number one supplier of affordable medicines in the US.

Strategy Generic Drugs

Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’

Following the formation of their partnership nearly five years ago, Alvotech and Fuji have together welcomed approval in Japan for Alvotech’s biosimilar to Stelara (ustekinumab).

Biosimilars Approvals

‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars

Marking a decade since Celltrion’s Remsima version of infliximab became the first monoclonal antibody biosimilar approved in Europe, Kevin Byoung Seo Choi, senior vice president and head of the marketing division at Celltrion Healthcare, talks to Generics Bulletin about the firm’s progress so far and the “room for improvement” that the company perceives in areas such as regulation, market access and pricing, supply chain and procurement – as well as what the future holds for the Korean biosimilars giant.

Biosimilars Europe
See All

Deals Explore this Topic

Set Alert for Deals

Glenmark Divests API Company, Setting Out On Distinct Journeys

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”

Commercial M & A

Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit

Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.

Legal Issues Deals

Abbott To Take mAbxience Biosimilars To Emerging Markets From 2025

European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.

Biosimilars Deals

Amgen’s $27.8bn Horizon Takeover Stipulates Biosimilar Restrictions

The FTC’s proposed consent order allowing Amgen to move ahead with its mammoth takeover of Horizon includes an interesting stipulation for industry – one involving biosimilars.

M & A Deals
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

Not In 2023 After All? FDA Turns Down Approval For Coherus’ On-Body Pegfilgrastim

Coherus BioSciences says that it will work closely with the US Food and Drug Administration and the unnamed third-party filler to obtain approval for its proposed version of Neulasta Onpro on-body injector “as quickly as possible.”

Biosimilars Value-Added Medicines

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

Director of the FDA’s center for drugs slams firm for failing to reach out before suspending operations in the wake of an inspection that raised serious data integrity concerns. Instead, firms should be alerting the agency as soon as they realize there could be shortages.

Manufacturing Generic Drugs

Glenmark Divests API Company, Setting Out On Distinct Journeys

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”

Commercial M & A

Alvotech Gets A Fresh Date For Adalimumab In US

Alvotech has revealed a US FDA goal date of 24 February 2024 for its refiled AVT02 proposed high-concentration interchangeable adalimumab biosimilar rival to Humira, as the firm provided further details of the resubmission – including an expected facility reinspection.

Biosimilars United States
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Adcock Remains Resilient In Tough Business Environment

Adcock saw its profits grow by 4.2% during FY 2024 despite a challenging economic environment.

Sales & Earnings South Africa

Aspen Appears Unfazed As Potential Difficulties Loom

Analysts posted wary notes about the prospects of South African pharmaceutical firm Aspen as its financial year came to an end, while management maintained confidence in the firm’s “solid results.”

Sales & Earnings Strategy

Glenmark Lays Out US Flovent Plans, Discusses Growing Debt Pile

India’s Glenmark is hoping that its proposed generic version of GlaxoSmithKline’s Flovent will benefit from a limited competition market, as it continues to plan a filing with the US Food and Drug Administration.

Strategy Sales & Earnings

Xbrane: We Are Not Convinced On European IQVIA Ranibizumab Data

Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.

Sales & Earnings Strategy
See All

People Explore this Topic

Set Alert for People

Biocon Gets A New Group CEO As Aflibercept Approval Arrives

Biocon has named Peter Bains as its new group CEO, as the firm’s Biocon Biologics business confirmed that its aflibercept biosimilar to Eylea had become the first to receive a formal European approval.

Executive Changes Leadership

Who’s Hired? Alvotech Names New COO After Refiling Adalimumab

Alvotech has appointed a fresh chief operating officer as it continues to pursue a US approval for its adalimumab biosimilar. Meanwhile, Strides Pharma Science’s strategy head has left the company and Nick Haggar has joined Biocon’s board, while US association the AAM has also welcomed new staff.

Executive Changes Leadership

Biocon Biologics Builds Out Management Team

As it continues to build on the biosimilars business gained from a major transaction with former partner Viatris, Biocon Biologics has announced a raft of executive appointments to bolster its management team.

Executive Changes Leadership

Hikma Hikes Generics Guidance As It Prepares For New CEO

After a tough 2022 for its generics business, Hikma is predicting big things for the division this year, raising its full-year guidance from 20% growth to nearly 30% as new CEO Riad Mishlawi prepares to take the reins from the start of September. Meanwhile, the firm has also picked up assets from Akorn following its collapse.

Sales & Earnings Generic Drugs
See All
UsernamePublicRestriction

Register